Yes ! Bertrand Godeau Centre de rfrence des cytopnies auto-immunes - - PowerPoint PPT Presentation

yes
SMART_READER_LITE
LIVE PREVIEW

Yes ! Bertrand Godeau Centre de rfrence des cytopnies auto-immunes - - PowerPoint PPT Presentation

CHU Henri MONDOR ASSISTANCE PUBLIQUE HPITAUX DE PARIS Is there still a role for splenectomy in ITP? Yes ! Bertrand Godeau Centre de rfrence des cytopnies auto-immunes de ladulte Service de mdecine interne CHU Henri Mondor,


slide-1
SLIDE 1

Is there still a role for splenectomy in ITP?

Yes !

Bertrand Godeau Centre de référence des cytopénies auto-immunes de l’adulte Service de médecine interne CHU Henri Mondor, 94000 Créteil, France bertrand.godeau@hmn.aphp.fr

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

CHU Henri MONDOR

slide-2
SLIDE 2
  • Retrospective review of 135 case series
  • 2623 patients
  • Complete response: 66 %

(follow-up 1 to 153 months)

  • Relapse: 15 %
  • Mortality with laparoscopy: 0.2 %
slide-3
SLIDE 3

The long-term prognosis of splenectomized patients is favorable, even in the subgroup of patients who intially failed to respond to splenectomy ?

slide-4
SLIDE 4

With the development of new therapeutic strategies, Is there still a role for Splenectomy in ITP ?

  • Rituximab
  • Effective
  • Not expensive
  • Simple to administer
  • Can cure
  • Safety ?
  • No license
  • Long-term response:
  • nly 20% ?
slide-5
SLIDE 5

Is there still a role for Splenectomy in ITP ?

Con

  • Patients and physicians

reluctant …

  • Long term response ?
  • Long term safety ?
  • Is it possible to predict the

response (isotopic study ?)

Pro

  • Experience
  • Not

expensive

  • Cure
slide-6
SLIDE 6
  • Retrospective study using Delphi panel design
  • 610 patients (F, Ge, It, Sp, UK)
  • 6% of splenectomy
  • Strong consensus that first line treatment should be

corticosteroids (91%) and second line treatment splenectomy (71%)

  • Many physicians would modify their choice of treatment if

patients expressed concern about splenectomy (74%) or in presence of comorbidities Treatment practices in adults with chronic immune thrombocytopenia – a European perspective

Rodeghiero et al, European Journal of Haematology 2009; 84: 160-8

slide-7
SLIDE 7

Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review.

Mikhael et al Am J Hematol. 2009; 84:743-8.

  • 1,223 laparoscopic splenectomies
  • The pooled short-term surgical non-response rate:

8.2% (95% CI 5.4-11.0)

  • The pooled long-term relapse rate:

4,4 per 100 patient years (95% CI 2.8.-6.7)

Failure rate of 28% at 5 years

Splenectomy may have higher initial relapse rates, particularly, in the first 2 years after surgery, and the rate may decline over time

slide-8
SLIDE 8

Splenectomy Response to long term (late relapse) ?

Time to Splenectomy Failure in Patients with Recurrent

  • r Refractory Chronic Immune Thrombocytopenic

Purpura

Gregory Cheng1*, Terry Gernsheimer, MD2, Harold J. Olney, MD, CM3, James B. Bussel, MD4, Palvi Shah5*, Andres Brainsky6*, Kelly M. Grotzinger6* and Manuel Aivado6 50% of relapse during the first yr

slide-9
SLIDE 9
  • Infection
  • Malignancy ?
  • Vascular complications

– Arteriothrombosis – Venous thrombosis – Cardiovascular events – Pulmonary hypertension Complications of splenectomy

slide-10
SLIDE 10

Risk for hospital contact with infection in patients with splenectomy. A population-based cohort study

Thomsen et al, Ann Intern Med 2009; 151: 546-55

slide-11
SLIDE 11

Risk for hospital contact with infection in patients with splenectomy. A population-based cohort study

Thomsen et al, Ann Intern Med 2009; 151: 546-55

Splenectomized ITP patients n = 269 Non splenectomized ITP patients n = 1345 Adjusted RR (95% CI) Median days since splenectomy indicated 196 196 Infection involving hospital contact 0 to 90 d, n (%) 15 (5.6) 36 (2.7) 2.6 (1.3-5.1) 91 to 365 d, n (n p 100pt yr) 11 (5.7) 59 (6.5) 1 (0.5-2) > 365 d 56 (4.6) 173 (3.3) 1.4 (1-2)

slide-12
SLIDE 12

Risk for hospital contact with infection in patients with splenectomy. A population-based cohort study

Thomsen et al, Ann Intern Med 2009; 151: 546-55

slide-13
SLIDE 13

ITP: hyperexpression of Cell-derived microparticles

Fontana et al, Thrombosis Research 2008; 122: 599-603

slide-14
SLIDE 14

Splenectomy as a cause of Chronic Thromboembolism Pulmonary Hypertension (CTEPH) ?

Jaïs et al, Thorax 2005; 60: 1031-4

slide-15
SLIDE 15

Can the results of isotopic study help the clinicans to make the decision to perform splenectomy ?

slide-16
SLIDE 16

Autologous 111In-Labeled Platelet Sequestration Studies in Patients with Primary Immune Thrombocytopenia (ITP): A Report From the United Kingdom Registry

Ameet Sarpatwari, M.Phil1*, Drew Provan, MD2*, Ravin Sobnack, PhD3*, Sebhat Erqou, MD, M.Phil4*, F. W. David Tai, BSc.5*, Simon Sanderson, MD4* and Adrian Newland, MD, FRCP6

slide-17
SLIDE 17

Don’t forget splenectomy !

slide-18
SLIDE 18

Don’t forget splenectomy ?

  • Elderly
  • Contra-indication to splenectomy
  • severe comorbidities
  • Liver sequestration on isotopic study
  • Reluctant ?

TPO-r agonists

  • Young patients
  • Splenic or hepato/splenic sequestration
  • n isotopic study

Splenectomy